Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are all beta-lactams created equal?

D M Livermore1

  • 1Department of Medical Microbiology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, United Kingdom. D.M.Livermore@mds.qmw.ac.uk

Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia.

The Journal of hospital infection·2020
Same author

The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemases.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines.

The Journal of antimicrobial chemotherapy·2018
Same author

Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK.

The Journal of antimicrobial chemotherapy·2017
Same author

Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing.

The Journal of antimicrobial chemotherapy·2016

The development of beta-lactam antibiotics faces a constant battle against bacterial resistance. While newer drugs like carbapenems offer broad spectrum activity, emerging resistance mechanisms, particularly beta-lactamases, remain a significant challenge.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Beta-lactam antibiotics are a cornerstone of antibacterial therapy but are increasingly undermined by bacterial resistance.
  • The evolution of resistance, primarily through beta-lactamase enzymes and target modifications (penicillin-binding proteins), necessitates continuous drug development.
  • Achieving both broad-spectrum activity and stability against resistance mechanisms has been a persistent challenge across different beta-lactam classes.

Purpose of the Study:

  • To review the challenges and successes in developing beta-lactam antibiotics with improved spectrum of activity and resistance to enzymatic degradation.
  • To highlight the comparative efficacy and limitations of penicillins, cephalosporins, and carbapenems in combating bacterial resistance.
  • To discuss the emergence and spread of resistance mechanisms, particularly beta-lactamases, and their impact on antibiotic utility.

Related Experiment Videos

Main Methods:

  • Literature review and analysis of existing data on beta-lactam antibiotic classes.
  • Comparative assessment of spectrum of activity, beta-lactamase stability, and resistance emergence patterns.
  • Discussion of specific resistance mechanisms, including plasmid-mediated beta-lactamases (AmpC, TEM, SHV) and target alterations.

Main Results:

  • Penicillins offer spectrum or stability but rarely both; inhibitors are often needed but lack AmpC coverage.
  • Cephalosporins provide better combined spectrum and stability but struggle with comprehensive coverage (enterobacteria, anaerobes, etc.) and enterococcal resistance.
  • Carbapenems offer the broadest spectrum among beta-lactams, with slower emergence of resistance compared to cephalosporins, though concerning resistance reports are emerging.

Conclusions:

  • The development of beta-lactams is an ongoing evolutionary race against bacterial resistance.
  • Carbapenems represent the most potent beta-lactams currently available, but vigilance against emerging resistance is crucial.
  • Understanding resistance mechanisms is key to designing future beta-lactam antibiotics that can overcome bacterial defenses.